NCT01881971 (SPARC) is a EARLY_PHASE1 clinical trial of Rouvastatin calcium in HIV Seropositivity, sponsored by Alison Morris.

Who is sponsoring NCT01881971?

NCT01881971 is sponsored by Alison Morris.

What drugs are being tested in NCT01881971?

Interventions in NCT01881971: Placebo, Rouvastatin calcium.

What condition does NCT01881971 study?

NCT01881971 studies HIV Seropositivity.

Is NCT01881971 still recruiting?

NCT01881971 is currently completed. Last updated 6 October 2020.

Last reviewed 2020-10-06 · How we verify

NCT01881971: SPARC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multicenter, Prospective Adaptive Response Placebo-controlled Double-blind Study Comparing Effects of Rosuvastatin Versus Placebo

Completed EARLY_PHASE1 Last updated 6 October 2020

What this trial tests

EARLY_PHASE1 trial testing Placebo in HIV Seropositivity in 23 participants. Completed in 1 January 2016.

Timeline

1 May 2013

Primary endpoint
1 November 2015

1 January 2016

Quick facts

Lead sponsor	Alison Morris
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	23
Start date	1 May 2013
Primary completion	1 November 2015
Estimated completion	1 January 2016
Sites	3 locations across United States

Drugs / interventions tested

Placebo
Rouvastatin calcium — full drug profile →

Conditions studied

HIV Seropositivity — all drugs for HIV Seropositivity →

Sponsor

Alison Morris — full company profile →

Who can join

Adults 18 to 80, any sex, with HIV Seropositivity. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

change in inflammatory markers - hsCRP
Time frame: 24 weeks
To assess change in hsCRP after 24 weeks of therapy with rosuvastatin

Sponsor's own description

Hypothesis: Statin therapy will decrease inflammation and slow progression of cardiopulmonary abnormalities in HIV.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Immune activation and cardiovascular disease in chronic HIV infection.
Longenecker CT, Sullivan C, Baker JV. · · 2016 · cited 85× · PMID 26599166 · DOI 10.1097/coh.0000000000000227
Coronary Artery Disease in HIV-Infected Patients: Downside of Living Longer.
Lacson JC, Barnes RP, Bahrami H. · · 2017 · cited 29× · PMID 28265887 · DOI 10.1007/s11883-017-0651-4
Statins to improve cardiovascular outcomes in treated HIV infection.
Longenecker CT, Eckard AR, McComsey GA. · · 2016 · cited 25× · PMID 26658651 · DOI 10.1097/qco.0000000000000223
Use of rosuvastatin in HIV-associated chronic obstructive pulmonary disease.
Morris A, Fitzpatrick M, Bertolet M, Qin S, et al · · 2017 · cited 19× · PMID 27941393 · DOI 10.1097/qad.0000000000001365

Verify or expand the search:

Other recruiting trials for HIV Seropositivity

Currently open trials in the same condition.

NCT06799650 — Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV · Phase 2 · recruiting
NCT05122026 — Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics · Phase 1, PHASE2 · active not recruiting
NCT05118490 — Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Is · Phase 4 · active not recruiting
NCT05723653 — Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention · NA · recruiting
NCT04832477 — Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01881971 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alison Morris
Last refreshed: 6 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01881971.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing